• 21 March 2018

    Pfizer’s rituximab biosimilar edges closer to approval

    Pfizer’s rituximab biosimilar candidate, PF-05280586, edged closer towards approval on January 24, 2018, when the company announced positive top-line results in a Phase III trial in follicular lymphoma (FL).

  • 19 March 2018

    Digital health: a new direction for neurology

    Recent years have shown a large increase in investment towards digital health, a multifaceted segment in the industry that can combine software-based therapies into different aspects of the drug development...

  • 15 March 2018

    2018 is the year for making strategic alliances in DMD

    Duchenne Muscular Dystrophy (DMD) is a rare neuromuscular degenerative disease that affects 15 in every 100,000 males (CDC, 2018). There is currently no effective therapy to treat the disease. However,...

  • 14 March 2018

    Blockbuster oncology deal for Merck and Eisai

    On 7 March, Merck completed a major strategic collaboration for the global co-development and co-commercialisation of Eisai oncology drug Lenvima (lenvatinib mesylate) worth up to $5.76B.

  • 2 March 2018

    Biopharma financing showed healthy growth in January

    When reviewing the financing leads that occurred in January 2018, GlobalData has determined that more financing leads occurred and more funding for biopharmaceutical companies was secured in January compared to...